Ipca Laboratories Ltd (IPCALAB)
·Next Day Close·-1.45%·₹1,963.25
Key EventInsider trading window closure announced
IPCA Laboratories Limited (IPCALAB)
·Next Day Close·+0.34%·₹1,889.85
Key EventIPCA Laboratories revises FY27 growth outlook upward to 14-16% on strong Q1 performance and margin resilience
ImpactShareholders should note upwardly revised growth expectations and margin expansion potential from biosimilars and capacity investments, though material cost pressures remain a near-term riskSign up to read impact
IPCA Laboratories Limited (IPCALAB)
·Next Day Close·-3.5%·₹1,733.65
Key Event76th AGM approved FY2026 audited financials and declared dividend
ImpactShareholders approved key financials and leadership appointments, confirming governance continuity.Sign up to read impact
IPCA Laboratories Limited (IPCALAB)
·Next Day Close·-3.5%·₹1,733.65
Key EventBoard approved Q1 FY27 results and Krebs Biochemicals amalgamation
ImpactThe company delivered strong top-line growth and profitability, with exceptional items clarifying non-recurring impacts ahead of a strategic amalgamation.Sign up to read impact
IPCA Laboratories Limited (IPCALAB)
·Next Day Close·+0.2%·₹1,736.85
Key EventIPCA Labs schedules Q1FY27 earnings conference call for August 14, 2026
ImpactInvestors can participate in the call to hear management discuss quarterly results and business outlook.Sign up to read impact
IPCA Laboratories Limited (IPCALAB)
·Next Day Close·+2.04%·₹1,877.6
Key EventRecord date set for dividend entitlement ahead of AGM
ImpactShareholders on the record date will receive a dividend of Rs. 6 per share.Sign up to read impact
IPCA Laboratories Limited (IPCALAB)
·Next Day Close·+0.88%·₹1,840.05
Key EventCertificate issued under SEBI Regulation 74(5) for quarter ended June 30, 2026
ImpactThe filing confirms routine compliance with shareholding reporting requirements and no material changes in shareholding structure.Sign up to read impact
Ipca Laboratories Ltd (IPCALAB)
·Next Day Close·-0.34%·₹1,696.45
Key EventIpca Laboratories reported Q1 FY27 revenue growth of 13% in India's formulation segment to INR1,082 crores and 34% export growth to INR603 crores, with consolidated EBITDA margin expanding to 22.88% YoY.
ImpactShareholders should note improved profitability and biosimilars pipeline progress, though near-term growth faces material cost inflation pressures.Sign up to read impact
IPCA Laboratories Limited (IPCALAB)
·Next Day Close·+1.9%·₹1,648.45
The board approved the amalgamation of Krebs Biochemicals & Industries Ltd. with Ipca Laboratories, effective April 1, 2026, following all required approvals. The merger creates operational synergies, consolidates pharmaceutical manufacturing, secures critical API supply, and reduces administrative burdens. Shareholding remains stable with promoters at 44.66% and public at 55.34% post-merger.
Sign up to read summaryIPCA Laboratories Limited (IPCALAB)
·Next Day Close·+1.9%·₹1,648.45
The board approved the merger of Krebs Biochemicals & Industries into Ipca Laboratories, subject to regulatory approvals, with an effective date of April 1, 2026. The scheme involves issuing 7 new shares of Re. 1 each for every 200 shares held by Krebs shareholders, resulting in minimal promoter share dilution and a slight public shareholding increase. The merger aims to create operational synergies, secure critical fermentation-based APIs, and reduce administrative burdens, while Krebs' loss-making operations will benefit from Ipca's financial and technical resources.
Sign up to read summary